Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (3945)	5/31/2001 5:31:10 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

IJ, I'm betting that there is a (substantial) corner of the market that is price sensitive. That might change if Medicare starts prescription coverage though. I haven't seen the script numbers recently. What period were you looking at? From their last quarter PR: Niaspan prescriptions continued to show strong growth, increasing 36 percent from the comparable quarter a year ago, nearly twice the rate of growth of the cholesterol market. ... Kos continues to expect revenue to increase 40-45 percent for the year 2001 compared with 2000, with the growth concentrated in the second half of the year, consistent with normal seasonal patterns for prescriptions and wholesale purchases. A combo with a "real" statin would be dynamite for the company. It would require new trials, and I've no idea if the existing agreement with du Pont would preclude such a deal. Sure doctors could prescribe a combo now. However there is concern with pill count and simplicity. Further, KOSP just don't have the marketing strength to push this by themselves. Incidentally, in a couple of years SEPR will have a sizeable but somewhat under-utilized primary-care sales force (just two or three products at the beginning). Wouldn't surprise me to see them co-promote a product like this. (But one in a related allergy/asthma field would of course be better). Peter